Health Catalyst (HCAT) Scheduled to Post Earnings on Wednesday

Health Catalyst (NASDAQ:HCAT) will be announcing its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.10 per share for the quarter. Health Catalyst has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The firm had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. During the same quarter in the prior year, the firm earned ($0.21) EPS. Health Catalyst’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, analysts expect Health Catalyst to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Health Catalyst Stock Performance

Shares of Health Catalyst stock opened at $7.68 on Tuesday. The company has a market capitalization of $464.41 million, a P/E ratio of -5.12 and a beta of 1.32. Health Catalyst has a 1 year low of $5.42 and a 1 year high of $11.41. The company’s fifty day moving average is $7.96 and its two-hundred day moving average is $7.08.

Insider Buying and Selling

In other news, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the sale, the chief operating officer now directly owns 140,108 shares in the company, valued at approximately $1,062,018.64. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the transaction, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,187 shares of company stock valued at $226,171. Corporate insiders own 2.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HCAT. Piper Sandler lowered their price target on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research note on Friday, October 4th. Evercore ISI upped their price target on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. JPMorgan Chase & Co. increased their price target on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Finally, Stephens dropped their price objective on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.90.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.